LOTTE BIOLOGICS was established in 2022, and is headquartered in Seoul, South Korea. The company entered the pharmaceutical industry as a CDMO company with the acquisition of Bristol-Myers Squibb’s Syracuse manufacturing site.
By providing innovative medicines to patients, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.
As one of the top-5 corporations in Korea, LOTTE has various business units, including petro/fine chemicals, food, retail, hotels, electronics, construction, and IT. LOTTE creates a sustainable future by continuously seeking out innovation and taking on new challenges in over 30 countries around the world, including the US and Europe.